A Clinical Investigation of the Adjustable Continence Therapy (ACT®) for Female Stress Urinary Incontinence Due to Intrinsic Sphincter Deficiency

Date Added
May 25th, 2021
PRO Number
Pro00103696
Researcher
Eric Rovner

List of Studies


Keywords
Bladder, Women's Health
Summary

This study is for females 22 years or older who have been diagnosed with stress urinary incontinence with primary intrinsic sphincter deficiency. Subjects are being invited to take part in a research study using a device called the ACT (Adjustable Continence Therapy for Women). ACT is an adjustable implantable silicone device for the treatment of unwanted loss of urine during activity (stress incontinence). The purpose of this study will be to find out if the implant of the ACT is safe and effective in reducing unwanted urine loss. The study will involve about 167 women that have unwanted urine loss. Participation is voluntary. This system is investigational which means it is not approved by the U.S Food and Drug Administration (FDA). After placement of the devices, subjects will be followed for 12 months on a regular visit schedule. Annual visits may continue for up to 5 years (subjects will only come to clinic one time a year after the first year in the study).

Institution
MUSC
Recruitment Contact
Jessica Jenkins
843-876-0630
jenkijn@musc.edu

A prospective efficacy study comparing FREquency of use and Efficacy of a personalized surgery-free wearable and personalized bladder modulation system with objective confirmation of nerve activation for use in the home by subjects with OverActive Bladder syndrome

Date Added
December 8th, 2020
PRO Number
Pro00103694
Researcher
Eric Rovner

List of Studies


Keywords
Bladder
Summary

The purpose of this research study is to compare the effectiveness of one treatment per week to three treatments per week using the non-surgical bladder modulation system for those diagnosed with OverActive bladder syndrome (OAB) in the home environment. Subjects Male or Female over the age of 18 with a diagnosis of Overactive bladder who meet all inclusion and no exclusion criteria will be eligible to enroll in a new study. This study will test a new surgey free wearable and personalized bladder modulation system.

Institution
MUSC
Recruitment Contact
Jessica Jenkins
843876-0630
jenkijn@musc.edu

Single Institution Registry of Prostatic Artery Embolization for Lower Urinary Tract Symptoms due to Benign Prostatic Obstruction

Date Added
March 13th, 2020
PRO Number
Pro00097914
Researcher
Andre Uflacker

List of Studies


Keywords
Aging, Bladder
Summary

This study will collect prospective data on clinical indications, outcomes, and adverse events related to Prostatic Artery Embolization (PAE) at the Medical University of South Carolina. Patients undergoing surgical treatment for benign prostatic obstruction causing LUTS will also be allowed to enroll in this registry for the purposes of comparison. Patients will be followed at 1, 3, and 12 months post-procedure, for a period of up to 5 years. Patients will remain enrolled in the registry for a period of 5 years.

Institution
MUSC
Recruitment Contact
Andre Uflacker
8438765556
uflackera@musc.edu

Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer

Date Added
December 2nd, 2019
PRO Number
Pro00094604
Researcher
Theodore Gourdin

List of Studies


Keywords
Bladder, Cancer/Genitourinary
Summary

This study is for patients with bladder cancer. The purpose is to compare the effects, good and/or bad, of chemotherapy and radiation therapy with or without the use of atezolizumab,

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu



-- OR --